Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
RSNA 2023 spotlight: Sectra empowers improved work-life balance for radiologists
In booth #8113, Sectra will showcase the complete enterprise imaging portfolio comprised of imaging modules (radiology, cardiology, pathology, orthopaedics, and ophthalmology), with its VNA and Best in KLAS PACS at its core—all delivered as a cloud service. In booth #8113, Sectra will showcase the complete enterprise imaging portfolio comprised of imaging modules (radiology, cardiology, pathology, orthopaedics, and ophthalmology), with its VNA and Best in KLAS PACS at its core—all delivered…
PR Newswire
07/11/2023
Antech launches first comprehensive veterinary diagnostics offering in the UK…
Antech, a trusted partner in delivering veterinary diagnostics for more than 35 years, brings to the UK a complete portfolio that spans reference laboratory services, in-house diagnostics, comprehensive imaging and technology solutions, advanced telemedicine services and innovative rapid diagnostics. Antech, a trusted partner in delivering veterinary diagnostics for more than 35 years, brings to the UK a complete portfolio that spans reference laboratory services, in-house diagnostics,...
PR Newswire
07/11/2023
Calliditas Interim Report January - September 2023
Financial Summary of Q3 2023 Financial Summary of Q3 2023 July 1–September 30, 2023 January 1 - September 30, 2023 "The recent ASN meeting inPhiladelphiaprovided us with numerous opportunities to meet and engage with nephrologists across the country, further cementing our belief that the strong long-term data from our Phase 3 trial, in combination with a potential full approval, will significantly impact how nephrologists view and use the product...
PR Newswire
07/11/2023
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel…
BRY812 uses the proprietary CysLink™ irreversible chemical conjugation technology platform and highly stable linker to conjugate the antibody with the toxin. BRY812 has shown significant tumor growth inhibition in preclinical studies, and demonstrated excellent anti-tumor activity that is potentially superior to similar drugs. Compared to other drugs of the same class, it exhibits higher circulation stability, effective release of the payload within the tumor while significantly reducing toxin…
PR Newswire
07/11/2023
Mithra's NEXTSTELLIS® granted additional patent in the United States
Mithra's NEXTSTELLIS ®granted additional patent in the United States New patent extends protection for NEXTSTELLIS ®(ESTELLE ® ) until 2036Mayne Pharma has a 20-year exclusive license and supply agreement in the US and Australia for NEXTSTELLIS ®Liege, Belgium, 07 November 2023 – 07:00 CET– Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, announces today that it has been...
Nasdaq GlobeNewswire
07/11/2023
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
Vivoryon Therapeutics N.V. to Present at UpcomingInvestor ConferenceHalle (Saale) / Munich, Germany, November 7, 2023– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company's management will present at the following conference: Jefferies London Healthcare...
Nasdaq GlobeNewswire
07/11/2023
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare…
Saint-Herblain (France), November 7, 2023 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies London Healthcare Conference, to take place November 14-16, 2023 in London, UK.Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host a fireside chat at 2:30pm GMT on November 14 to discuss...
Nasdaq GlobeNewswire
07/11/2023
LEQEMBI® Q3 2023 sales published - 0.4 billion yen recorded in the period
BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET. BioArctic's complete interim report for the third quarter 2023 will be published onNovember 8at08:00 CET. --- This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, onNovember 7, 2023, at04:40 a.m...
PR Newswire
07/11/2023
Nayo Biotechnology to Unveil New Product A8 Pro at Medica 2023, Empowering…
Key features of A8 Pro include: Key features of A8 Pro include: The MEDICA exhibition will take place in Düsseldorf,GermanyfromNovember 13th to 16th, 2023. Visitors to the exhibition are invited to visit Nayo Biotechnology's booth, number 3H14-2, to engage with the team and explore the boundless potential offered by the A8 PRO. At MEDICA 2023, Nayo Biotechnology will showcase the fusion of innovative technology and superior quality, collaborating with all to create a better future...
PR Newswire
07/11/2023
Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at…
Oral Presentation Analyses Oral Presentation Analyses NefIgArd Phase 3 Trial full analysis The Phase 3 double-blind, randomized NefIgArd study evaluated the impact of Nefecon, a novel targeted-release formulation of budesonide, vs placebo on eGFR in adults with IgAN. The 2-year study period consisted of nine months of treatment with Nefecon (16 mg/day) or placebo, followed by a 15-month follow-up period off the study drug. The full analysis of the 364 patients randomized 1:1 to...
PR Newswire
07/11/2023
Generative AI in Healthcare Market to Reach $30.4 Billion, by 2032 at 34.9%…
Request Sample of the Report on Generative AI in Healthcare Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/157159 Request Sample of the Report on Generative AI in Healthcare Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/157159 Prime determinants of growth The generative AI in healthcare market has experienced significant growth due to surge in adoption of the generative AI for medical diagnosis by analyzing the medical...
PR Newswire
07/11/2023
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for…
Daewoong Therapeutics (CEO Bokki Kang), a subsidiary of Daewoong Pharmaceutical, has completed preclinical studies and compiled data for a microneedle patch within the Semaglutide series, a GLP-1 analogue, using its proprietary 'CLOPAM' (Closed-Packed Aeroperssured Microneedle) platform. This platform is secured by 6 international (Patent Cooperation Treaty, PCT) and 23 domestic patents, of which 5 are registered, encompassing various aspects of manufacturing and packaging. The technology…
PR Newswire
07/11/2023
Emerging Market Trends in Muscular Dystrophy: A DelveInsight Analysis of Becker…
DelveInsight has recently released a series of epidemiology-based market reports focusing on muscular dystrophy including Becker Muscular Dystrophy, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, and Limb-girdle Muscular Dystrophy. These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2019 to 2032 segmented into…
PR Newswire
06/11/2023
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I NATHALI-01 Trial evaluating UCART20x22 in r/r B-cell NHL to be presented at ASH 65 thAnnual meeting.Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL...
Nasdaq GlobeNewswire
06/11/2023
Monthly information regarding the total number of voting rights and total number…
Monthly information regarding the total number of voting rights andtotal number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of theAutorité des Marchés Financiers )Market : NYSE Euronext ParisISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights10/31/2023 96,288,553 Total gross of voting rights: 96,288,553 ...
Nasdaq GlobeNewswire
06/11/2023
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…
Bagsværd, Denmark, 6 November 2023— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
06/11/2023
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter…
Individuals may participate in the live call via telephone by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) and using the conference ID: 13741546. Participants are asked to dial in 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call via the “News & Media” section of the company's website,https://www.therivabio.com, under “Events” or by clickinghere, up to 90 days after the call...
Nasdaq GlobeNewswire
06/11/2023
ENDO REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTS
(in thousands, except per share amounts) (in thousands, except per share amounts) __________ CONSOLIDATED FINANCIAL RESULTS Total revenues were$452 millionin third-quarter 2023, a decrease of 17% compared to$542 millionin third-quarter 2022. This decrease was primarily attributable to decreased revenues from the Generic Pharmaceuticals and Sterile Injectables segments. Reported loss from continuing operations in third-quarter 2023 was$28 millioncompared to...
PR Newswire
06/11/2023
Inventiva announces a late breaker abstract and two additional abstracts on its…
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected for presentation. The two abstracts show: the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of...
Nasdaq GlobeNewswire
06/11/2023
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 06 November 2023– The execution of Novo Nordisk A/S' overall share repurchase programme for 2023 of DKK 30 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 4.1 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). The purpose of the...
Nasdaq GlobeNewswire
06/11/2023
Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings…
Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings A/S under the 2023 share repurchase programm – Today, Novo Nordisk A/S has entered into an agreement to purchase 7,012,500 B shares of DKK 0.10 at a value of DKK 4,886 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2023 share repurchase programme of up to a total of DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. The transaction price is DKK 696...
Nasdaq GlobeNewswire
06/11/2023
ResoTher Pharma receives a €2.5 million grant from European Innovation Council…
The project focusing on development of Resother Pharmas RTP-026 compound is one of 47 projects selected to receive funding out of 648 full proposals submitted for evaluation to the EIC-accelerator program. The grant given to ResoTher Pharma is defined as a "Grant first," meaning that the project will be considered for further support by the European Investment Bank upon completion of the Phase 2a study supported by the current grant. The project focusing on development of Resother…
PR Newswire
06/11/2023
Information on the Total Number of Voting Rights (Denominator) following…
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven, BELGIUM, Boston, MA, US – November 6, 2023 – 08.00 PM CET– In...
Nasdaq GlobeNewswire
06/11/2023
Genetic Testing Market to Reach $40.9 Billion by 2032, Exhibiting a CAGR of…
Request Sample of the Report on Genetic Testing Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/5241 Request Sample of the Report on Genetic Testing Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/5241 Prime determinants of growth Rise in prevalence of genetic diseases such as down syndrome sickle cell disease, phenylketonuria and others and increase in number of adoptions of genetic testing for diagnosis of cancer is...
PR Newswire
06/11/2023
Altri Comunicati
